在帕金森病中结步态的下丘脑和阴部刺激:随机试点试验
Carlo Alberto Artusi1,2, Claudia Ledda1,2, Silvia Gallo3
1Department of Neurosciences Rita Levi Montalcini, University of Turin, Turin, Italy.
Journal of Parkinson's disease
|February 17, 2025
概括
在帕金森病患者中,结合体下和黑色物质刺激并没有显著改善步态结,但三分之一的人看到有意义的好处,并更喜欢这种方法.
科学领域:
- 神经学 神经学
- 神经外科 神经外科
- 运动障碍 运动障碍
背景情况:
- 步态结 (FoG) 是一种严重的帕金森病 (PD) 症状,该症状对多巴胺类药物治疗和脑下深层刺激 (STN-DBS) 等标准治疗有抗性.
- 黑色物质网状体 (SNr) 刺激为改善FoG提供了潜在的治疗途径.
研究的目的:
- 调查STN-DBS和SNR刺激在PD患者的FOG上不同频率的联合STN-DBS和SNR刺激的疗效.
- 评估联合刺激对运动并发症,轴心症状,日常活动,精神状态和睡眠的影响.
主要方法:
- 一个双盲,随机,交叉试验试验与15名已经接受STN-DBS的PD患者进行.
- 参与者接受了三个一个月的治疗期:单独高频STN-DBS (S),联合高频STN-DBS和高频SNR刺激 (C1),以及联合高频STN-DBS和低频SNR刺激 (C2).
- 主要结局指标是新结走势问卷 (NFOG-Q) 得分的变化.
主要成果:
- 仅STN-DBS (S),C1和C2.2之间没有观察到NFOG-Q得分的统计学上显著差异.
- 然而,大约三分之一的患者经历了临床显著改善 (≥8分) 的FoG与联合刺激.
- 与单独使用STN-DBS相比,联合STN-SNr刺激 (C1和C2) 显著改善了运动并发症 (p <0.05).
- 值得注意的是,80%的患者在盲目评估期间表示他们更喜欢联合STN-SNr刺激.
- 所有报告的不良事件都是可以管理的.
结论:
- 虽然在初级终点上没有统计学意义,但联合STN-SNr刺激在一组PD患者中对FoG产生了临床益处.
- 大多数患者更喜欢联合刺激,这表明潜在的以患者为中心的优势.
- 结合STN-SNr刺激在管理运动并发症和提高睡眠质量方面被证明是安全有效的,这需要进一步的研究.
相关概念视频
Parkinson's Disease: Treatment
187
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
187
Parkinson's Disease: Overview
429
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
429


